Parameters Influencing Achievement of CR
| Parameters . | Patients Who Achieved CR (patients) . | Patients Refractory to Treatment (patients) . | P Value . |
|---|---|---|---|
| In Vitro Resistance Parameters | |||
| MDR1 expression | |||
| RT-PCR* | 0.092 ± 0.087 | 0.197 ± 0.022 | .04# |
| Flow cytometry† | 2.10 ± 0.59 | 3.93 ± 2.27 | .04# |
| MRP1 expression | |||
| RT-PCR* | 0.212 ± 0.341 | 0.756 ± 0.312 | .05# |
| Flow cytometry† | 1.38 ± 0.53 | 1.90 ± 0.43 | .05# |
| Mvp/LRP expression | |||
| RT-PCR* | 0.57 ± 0.51 | 0.69 ± 0.66 | NS |
| Flow cytometry† | 3.7 ± 1.7 | 4.4 ± 3.1 | NS |
| Modulatory effect of CsA on calcein-AM uptake‡,2-153 | 1.17 ± 0.27 | 1.55 ± 0.37 | .05# |
| Modulatory effect of probenecid on calcein-AM uptake‡,2-155 | 1.12 ± 0.36 | 1.39 ± 0.22 | .04# |
| Modulatory effect of CsA + probenecid on calcein-AM uptake‡,2-154 | 1.35 ± 0.47 | 2 ± 0.54 | .008# |
| LC50 DNR (μmol/L) | 0.29 ± 0.28 | 0.56 ± 1.32 | .05# |
| LC50 AraC (μmol/L) | 5.0 ± 8.8 | 17.2 ± 28.5 | .06# |
| LC50 etoposide (μmol/L) | 14.9 ± 17.3 | 20.4 ± 28.5 | NS# |
| Clinical and Biological Parameters | |||
| Age (yr) | 48 ± 16 | 62 ± 22 | .03# |
| WBC at diagnosis (×109/L) | 77 ± 72 | 139 ± 111 | .03# |
| CD34 (% of positive patients) | 54 | 64 | NS2-160 |
| Cytogenetic (%) | .052-164 | ||
| Good | 88 | 12 | |
| Intermediate | 58 | 42 | |
| Poor | 40 | 60 | |
| Parameters . | Patients Who Achieved CR (patients) . | Patients Refractory to Treatment (patients) . | P Value . |
|---|---|---|---|
| In Vitro Resistance Parameters | |||
| MDR1 expression | |||
| RT-PCR* | 0.092 ± 0.087 | 0.197 ± 0.022 | .04# |
| Flow cytometry† | 2.10 ± 0.59 | 3.93 ± 2.27 | .04# |
| MRP1 expression | |||
| RT-PCR* | 0.212 ± 0.341 | 0.756 ± 0.312 | .05# |
| Flow cytometry† | 1.38 ± 0.53 | 1.90 ± 0.43 | .05# |
| Mvp/LRP expression | |||
| RT-PCR* | 0.57 ± 0.51 | 0.69 ± 0.66 | NS |
| Flow cytometry† | 3.7 ± 1.7 | 4.4 ± 3.1 | NS |
| Modulatory effect of CsA on calcein-AM uptake‡,2-153 | 1.17 ± 0.27 | 1.55 ± 0.37 | .05# |
| Modulatory effect of probenecid on calcein-AM uptake‡,2-155 | 1.12 ± 0.36 | 1.39 ± 0.22 | .04# |
| Modulatory effect of CsA + probenecid on calcein-AM uptake‡,2-154 | 1.35 ± 0.47 | 2 ± 0.54 | .008# |
| LC50 DNR (μmol/L) | 0.29 ± 0.28 | 0.56 ± 1.32 | .05# |
| LC50 AraC (μmol/L) | 5.0 ± 8.8 | 17.2 ± 28.5 | .06# |
| LC50 etoposide (μmol/L) | 14.9 ± 17.3 | 20.4 ± 28.5 | NS# |
| Clinical and Biological Parameters | |||
| Age (yr) | 48 ± 16 | 62 ± 22 | .03# |
| WBC at diagnosis (×109/L) | 77 ± 72 | 139 ± 111 | .03# |
| CD34 (% of positive patients) | 54 | 64 | NS2-160 |
| Cytogenetic (%) | .052-164 | ||
| Good | 88 | 12 | |
| Intermediate | 58 | 42 | |
| Poor | 40 | 60 | |
Abbreviation: NS, not significant.
Variations between samples in cDNA synthesis were normalized by their relative quantities of β2m amplified by 23-cycle PCR. The normalized yield of MDR products relative to β2m were then compared with those of A549 cells for MRP1 and LRP and with those of HL60 Pgp for MDR1, which were defined as 1 arbitrary unit.
Values were expressed as adjusted for control, ie, the ratio of MoAbs fluorescence divided by control antibody fluorescence.
Data were calculated as the ratio of drug fluorescence with modulator divided by drug fluorescence without modulator after subtraction of the fluorescence of the control.
Quantified Pgp activity.
Quantified MRP1 activity.
Quantified the simultaneous activity of Pgp and MRP1.
#Using U Mann Whitney test.
Using χ2 test.
Using Kruskal Wallis test.